Cargando…

Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein

Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG (35‐55)‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to...

Descripción completa

Detalles Bibliográficos
Autores principales: Doronin, Vasilii B., Parkhomenko, Taisiya A., Korablev, Alexey, Toporkova, Ludmila B., Lopatnikova, Julia A., Alshevskaja, Alina A., Sennikov, Sergei V., Buneva, Valentina N., Budde, Thomas, Meuth, Sven G., Orlovskaya, Irina A., Popova, Nelly A., Nevinsky, Georgy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717850/
https://www.ncbi.nlm.nih.gov/pubmed/26493273
http://dx.doi.org/10.1111/jcmm.12704
_version_ 1782410699049271296
author Doronin, Vasilii B.
Parkhomenko, Taisiya A.
Korablev, Alexey
Toporkova, Ludmila B.
Lopatnikova, Julia A.
Alshevskaja, Alina A.
Sennikov, Sergei V.
Buneva, Valentina N.
Budde, Thomas
Meuth, Sven G.
Orlovskaya, Irina A.
Popova, Nelly A.
Nevinsky, Georgy A.
author_facet Doronin, Vasilii B.
Parkhomenko, Taisiya A.
Korablev, Alexey
Toporkova, Ludmila B.
Lopatnikova, Julia A.
Alshevskaja, Alina A.
Sennikov, Sergei V.
Buneva, Valentina N.
Budde, Thomas
Meuth, Sven G.
Orlovskaya, Irina A.
Popova, Nelly A.
Nevinsky, Georgy A.
author_sort Doronin, Vasilii B.
collection PubMed
description Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG (35‐55)‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to assess the production of catalytically active immunoglobulin G (IgG) antibodies or abzymes which have been shown to be present in sera of patients with several autoimmune diseases. Here, we show that IgGs from the sera of control C57BL/6 mice are catalytically inactive. During development of EAE, a specific reorganization of the immune system of mice occurred leading to a condition which was associated with the generation of catalytically active IgGs hydrolysing DNA, myelin basic protein (MBP) and MOG which was associated with increased proteinuria, changes in differentiation of mice bone marrow hematopoietic stem cells (HSCs) and an increase in proliferation of lymphocytes in bone marrow, spleen and thymus as well as a significant suppression of cell apoptosis in these organs. The strongest alterations were found in the early disease phase (18–24 days after immunization) and were less pronounced in later EAE stages (40 days after EAE induction). We conclude that a significant increase in DNase and proteolytic activities of antibodies may be considered the earliest statistically significant marker of MOG‐induced EAE in mice. The possible differences in immune system reorganizations during preclinical phases of the disease, acute and late EAE, leading to production of different auto‐antibodies and abzymes as well other changes are discussed.
format Online
Article
Text
id pubmed-4717850
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47178502016-01-26 Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein Doronin, Vasilii B. Parkhomenko, Taisiya A. Korablev, Alexey Toporkova, Ludmila B. Lopatnikova, Julia A. Alshevskaja, Alina A. Sennikov, Sergei V. Buneva, Valentina N. Budde, Thomas Meuth, Sven G. Orlovskaya, Irina A. Popova, Nelly A. Nevinsky, Georgy A. J Cell Mol Med Original Articles Myelin oligodendrocyte glycoprotein (MOG) is an antigen of the myelin sheath, which may trigger immune cell responses and the production of auto‐antibodies in multiple sclerosis (MS). In this study, we used MOG (35‐55)‐induced experimental autoimmune encephalomyelitis (EAE), a model of human MS, to assess the production of catalytically active immunoglobulin G (IgG) antibodies or abzymes which have been shown to be present in sera of patients with several autoimmune diseases. Here, we show that IgGs from the sera of control C57BL/6 mice are catalytically inactive. During development of EAE, a specific reorganization of the immune system of mice occurred leading to a condition which was associated with the generation of catalytically active IgGs hydrolysing DNA, myelin basic protein (MBP) and MOG which was associated with increased proteinuria, changes in differentiation of mice bone marrow hematopoietic stem cells (HSCs) and an increase in proliferation of lymphocytes in bone marrow, spleen and thymus as well as a significant suppression of cell apoptosis in these organs. The strongest alterations were found in the early disease phase (18–24 days after immunization) and were less pronounced in later EAE stages (40 days after EAE induction). We conclude that a significant increase in DNase and proteolytic activities of antibodies may be considered the earliest statistically significant marker of MOG‐induced EAE in mice. The possible differences in immune system reorganizations during preclinical phases of the disease, acute and late EAE, leading to production of different auto‐antibodies and abzymes as well other changes are discussed. John Wiley and Sons Inc. 2015-10-23 2016-01 /pmc/articles/PMC4717850/ /pubmed/26493273 http://dx.doi.org/10.1111/jcmm.12704 Text en © 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Doronin, Vasilii B.
Parkhomenko, Taisiya A.
Korablev, Alexey
Toporkova, Ludmila B.
Lopatnikova, Julia A.
Alshevskaja, Alina A.
Sennikov, Sergei V.
Buneva, Valentina N.
Budde, Thomas
Meuth, Sven G.
Orlovskaya, Irina A.
Popova, Nelly A.
Nevinsky, Georgy A.
Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
title Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
title_full Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
title_fullStr Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
title_full_unstemmed Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
title_short Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein
title_sort changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in eae mice treated with myelin oligodendrocyte glycoprotein
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717850/
https://www.ncbi.nlm.nih.gov/pubmed/26493273
http://dx.doi.org/10.1111/jcmm.12704
work_keys_str_mv AT doroninvasiliib changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT parkhomenkotaisiyaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT korablevalexey changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT toporkovaludmilab changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT lopatnikovajuliaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT alshevskajaalinaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT sennikovsergeiv changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT bunevavalentinan changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT buddethomas changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT meuthsveng changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT orlovskayairinaa changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT popovanellya changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein
AT nevinskygeorgya changesindifferentparameterslymphocyteproliferationandhematopoieticprogenitorcolonyformationineaemicetreatedwithmyelinoligodendrocyteglycoprotein